Project Grant R01CA302719
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $532K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a Project Grant of $542,644 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate radiation-guided antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) treatment. The award, effective April 1, 2026 through March 31, 2031, supports research into a transformative therapeutic approach that leverages the discovery of Tax-Interacting Protein 1 (TIP1) as a...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to The Washington University (Office of Sponsored Research Services) effective May 14, 2026, under the Cancer Treatment Research program (CFDA 93.395). The grant supports research targeting Type 1 Regulatory T Cells (TR1) to enhance the efficacy of neoantigen cancer vaccines through June 30, 2028. The project delivers fundamental and applied laboratory research focused on elucidating the mechanisms...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $399,829 under the Cancer Treatment Research program (CFDA 93.395) to develop next-generation engineered T cells with enhanced persistence for cancer immunotherapy. The award, initiated April 1, 2026 and concluding March 31, 2028, supports research focused on rationally designing chimeric antigen receptor (CAR) T cells that incorporate 4-1BB (CD137) signaling domains to...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded $641,419 to Washington University's Office of Sponsored Research Services on May 7, 2026, for clinical translation research of a novel Meitner-Auger electron (MAE) positron emission tomography (PET) theranostic agent. The project, extending through April 30, 2031, focuses on developing and evaluating [77Br]Br-WC-DZ, a stable bromine-77 ligand targeting...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a $399,829 Project Grant on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on chimeric antigen receptor (CAR) dendritic cell (DC) immunotherapy for solid tumors. The project, which runs through April 30, 2028, will deliver mechanistic characterization and optimization of a novel DC-based therapeutic platform called AB7H3-TLR4 CAR-DCs—engineered...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...
- Federal Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded a Project Grant totaling $425,088 to Washington University's Office of Sponsored Research Services, with performance from May 1, 2026, through April 30, 2031, under the Cancer Cause and Prevention Research program (CFDA 93.393). Products and Services: This research project will deliver a comprehensive comparative analysis of lung cancer care delivery and patient outcomes between Medicare Advantage (MA) and...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $399,829 to Washington University's Office of Sponsored Research Services, effective July 1, 2026 through June 30, 2028, under the Cancer Treatment Research program (CFDA 93.395). The award supports research to elucidate the mechanistic connections between ADAR1 (Adenosine Deaminase Acting on RNA 1) activity and serine metabolism in triple-negative breast cancer (TNBC), with the goal of identifying...
- Federal Grant Award Summary The National Cancer Institute, under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded The Washington University a Project Grant of $645,414 on June 18, 2026, to support research on integrin-targeted positron emission tomography (PET) imaging and therapeutics for predicting and treating radiation-induced pulmonary fibrosis (RIPF). This five-year project, extending through May 31, 2031, will translate mechanistic understanding of RIPF into...